PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while TRVN shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
-100.00%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
100.00%
Gross profit growth exceeding 1.5x TRVN's 46.93%. David Dodd would verify competitive advantages.
100.00%
Margin change of 100.00% while TRVN shows flat margins. Bruce Berkowitz would examine quality advantage.
7.04%
R&D growth less than half of TRVN's 15.11%. David Dodd would verify if efficiency advantage is sustainable.
-5.63%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.59%
Operating expenses growth less than half of TRVN's 9.64%. David Dodd would verify sustainability.
2.59%
Total costs growth less than half of TRVN's 8.32%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
13.04%
D&A growth above 1.5x TRVN's 1.90%. Michael Burry would check for excessive investment.
-2.44%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-2.59%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-3.66%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while TRVN reduces burden. John Neff would investigate differences.
-10.34%
Net income decline while TRVN shows 20.06% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-10.26%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-10.26%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
0.08%
Share count increase while TRVN reduces shares. John Neff would investigate differences.
0.08%
Diluted share increase while TRVN reduces shares. John Neff would investigate differences.